Pharmaceutical Grade
CBG Isolate REQUEST COA Vantage Hemp’s Pharmaceutical Grade CBG Isolate is a cGMP process-validated pharmaceutical-grade cannabinoid API, offering >99% pure Cannabigerol (CBG) with non-detectable THC, CBD, and other plant-derived impurities.

Pharmaceutical Grade CBG Isolate

 

With emerging scientific evidence supporting CBG’s properties, this isolate presents significant commercial potential for drug developers engaged in early-stage pharmaceutical research and clinical trials.

 

Preclinical studies suggest CBG is an attractive candidate for FDA Investigational New Drug (IND) applications. Additionally, CBG has demonstrated broad-spectrum properties, positioning it as a potential ingredient in next-generation formulations.

 

In markets where minor cannabinoids like CBG are gaining traction in cosmeceutical and nutraceutical applications, companies seeking differentiation in non-THC formulations may incorporate CBG. From a quality assurance and procurement perspective, sourcing a cGMP-compliant CBG API ensures regulatory readiness for future drug approvals, enhances brand positioning in cannabinoid-based R&D, and supports market expansion in high-growth pharmaceutical sectors.

Read About Our CBG Launch

Key Characteristics of Pharmaceutical Grade CBG Isolate

 

    • >99% Cannabigerol (CBG) purity
    • THC-Free (non-detectable levels of Δ9-THC, Δ8-THC, THCA)
    • Manufactured under cGMP guidelines for pharmaceutical APIs
    • High stability, making it ideal for cosmeceutical, dermatological, and neurological research​

Regulatory and R&D Relevance

 

    • United States (FDA Preclinical Drug Research): CBG is gaining attention for multiple applications, making it a candidate for preclinical drug research under FDA’s IND program.